Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Enrolling ACRIA Trials

Winter 2002/2003

Standard of Care Treatment vs. ZEST Once-Daily Regimen

This study will determine whether HIV-positive individuals on an initial HAART regimen with a twice-daily or more frequent dosing schedule can successfully switch to a once-daily regimen.

The drugs being studied are Zerit XR, Epivir and Sustiva (ZEST) once a day. Those qualified will either remain on their current medications, or switch to the once daily regimen ZEST. The study will last approximately 48 weeks, during which time participants will attend nine scheduled visits at ACRIA. All blood tests, study visits, and study medications (Zerit XR, Epivir & Sustiva), as well as medications from the Standard Of Care arm that are manufactured by the sponsor, will be provided at no charge to the participants. Prescriptions will be written for any other anti-HIV drug.

You are eligible if you are HIV-positive, age 18 or over, and on an initial HAART regimen (one or more NRTIs, at least one agent must have a twice-daily dosing schedule, and no NNRTI in the past or in current regimen) and have two consecutive viral loads of less then 50 copies/mL. The first viral load result must be at least 90 days before the screening visit.

Advertisement
Study participants will be reimbursed $25 for each of nine visits to ACRIA.

For more information, contact Dr. Douglas Mendez at 212-924-3934 ext. 126 or Dr. Yuriy Akulov at 212-924-3934 ext. 124


RESIST 1: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients With Tipranavir

This study will determine the safety and efficacy of tipranavir (a protease inhibitor) boosted with low-dose ritonavir in multiple antiretroviral drug-experienced patients.

This study can last approximately 48 weeks, with 10-12 visits to ACRIA. All blood tests, study visits, and study medications will be provided by the sponsor. All patients must have previously received treatment from each of the three antiretroviral classes, have received at least two protease inhibitor-based regimens, have a viral load great than 1000 copies/mL, and be on a protease inhibitor regimen at the time of study entry. To enter the study, patients must have at least one primary protease inhibitor mutation, but no more than two mutations on specific condons.

Study participants will be reimbursed $25 for each visit.

For more information contact Dr. Douglas Mendez at 212-924-3934 ext. 126 or Dr. Yuriy Akulov at 212-924-3934 ext. 124.





  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by AIDS Community Research Initiative of America. It is a part of the publication ACRIA Update. Visit ACRIA's website to find out more about their activities, publications and services.
 

Tools
 

Advertisement